H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on uniQure (NASDAQ:QURE) N.V. on Friday, setting a price target of $73, which is approximately 10.52% above the present share price of $66.05.
Chattopadhyay expects uniQure N.V. to post earnings per share (EPS) of -$0.63 for the second quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in uniQure, with an average price target of $89.33.
The analysts price targets range from a high of $105 to a low of $73.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $104 thousand and a net profit of -$34.46 million. The company's market cap is $2.95 billion.
According to TipRanks.com, H.C. Wainwright analyst Debjit Chattopadhyay is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.4% and a 55.03% success rate.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.